Portfolio company
Phlox Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Cardior
This company develops RNA-based therapeutics designed to prevent, repair and reverse heart diseases for patients with cardiac dysfunctions.
Cardior Pharmaceuticals
This biopharmaceutical company develops RNA-based therapeutics to prevent and repair heart disease for patients with conditions such as heart failure and myocardial infarction.
Lexeo Therapeutics
This clinical-stage company develops gene therapies for patients with genetically defined cardiovascular diseases and Alzheimer's disease.
Rocket Pharma
This company develops gene therapies for patients with rare and devastating genetic cardiovascular and haematological diseases.
Brano Therapeutics
This company develops small-molecule inhibitors to treat heart failure and metabolic dysfunction for patients with cardiovascular diseases.
Affinia Therapeutics
This company develops rationally designed gene therapies and viral vectors for patients with heart and central nervous system diseases.
ARTHEx Biotech
This clinical-stage biotechnology company develops RNA-based treatments for patients with rare neuromuscular genetic diseases, including myotonic dystrophy type 1.
Marea Therapeutics
This biotechnology company develops medicines for cardiometabolic and cardioendocrine diseases using human genetic data for patients with unmet medical needs.